To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
For 30 years, the Pharmacology and Immunoanalysis (SPI) unit has been demonstrating its expertise in the development of immunoanalytical methods, physicochemical analyzes (especially LC-MS) and cell culture enabling it to address multiple issues concerning detection, quantification and future development of molecules of various and varied kinds.
The research carried out in SPI always connects with the fundamental aspects of the methodological and analytical developments and always integrates the "Therapeutic Innovation and Diagnostic" line of the CEA's Fundamental Research Division. Research is usually carried out in collaboration with academic partners or contract with industry or government partners.
The mission of the laboratory, based on the CEA site of Marcoule, is to develop methodologies and technologies for the detection of pathogens or toxic substances found in the environment or in biological samples / tissues and the discovery and validation of biomarkers for diagnosis. The research carried out at Li2D is based on his expert knowledge in microbiological, immunological, genetic, genomic, proteomic, bioinformatics and high-resolution mass spectrometry techniques.
The work done at the Food Immuno-Allergy Unit aims to develop tools and knowledge to assess, manage and if possible prevent food-related allergic risk. Indeed, food allergies are a major public health problem because of the increase in prevalence, but also the number of affected food and the severity of clinical symptoms they cause. Therefore, it is a challenge and a concern for the Food Industry and the Public Authorities in charge of the health of consumers to have means to assess, manage and if possible prevent the allergic risks of food. Finally, since its inception, the SPI has developed commercialization projects that proved particularly successful (Prion or bioterrorism agents dosage, for example), by the realization of numerous contractual studies or collaborative research with industrial partners in pharmaceuticals and diagnostics for over twenty years ("spin-off" from our developments).The existence of a strong quality policy also contributes to the identity of our service: the presence of two full-time quality professionals, accreditation of Good Laboratory Practices (ANSM) of LEMM and iso9001 certification of SPI obtained on December 2014 (LI2D in 2003).
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.